Results 161 to 170 of about 4,863 (192)

Siltuximab for multicentric Castleman disease

Expert Review of Hematology, 2014
Dysregulated secretion of IL-6 plays a pivotal role in the pathogenesis of Castleman disease (CD), a rare lymphoproliferative disorder. In contrast to unicentric CD for which surgery is considered the treatment of choice, there is no standard therapeutic approach for multicentric CD (MCD). Siltuximab (trade name: Sylvant, formerly known as CNTO 328) is
Yi-Chang, Liu, Katie, Stone, Frits, van Rhee   +2 more
openaire   +2 more sources

Dose selection of siltuximab for multicentric Castleman’s disease

Cancer Chemotherapy and Pharmacology, 2015
Siltuximab is a monoclonal antibody that binds to interleukin (IL)-6 with high affinity and specificity; C-reactive protein (CRP) is an acute-phase protein induced by IL-6. CRP suppression is an indirect measurement of IL-6 activity. Here, modeling and simulation of the pharmacokinetic (PK)/pharmacodynamic (PD) relationship between siltuximab and CRP ...
Christina L, Mayer, Lanyi, Xie, Rajesh, Bandekar, Ming, Qi, Helgi, van de Velde, Manjula, Reddy, Xiang, Qin, Hugh M, Davis, Thomas A, Puchalski   +8 more
openaire   +2 more sources

Targeting interleukin 6 signaling by monoclonal antibody siltuximab on cholangiocarcinoma

Journal of Gastroenterology and Hepatology, 2020
AbstractBackground and AimCholangiocarcinoma has an unimproved prognosis. Interleukin 6 (IL‐6) has an oncogenic potential in some cancer diseases. However, the role of IL‐6 in cholangiocarcinoma carcinogenesis is not well understood. The current study investigated the role of IL‐6 signaling in cholangiocarcinoma carcinogenesis and efficacy of ...
Mai Ly Thi Nguyen, Khac Cuong Bui, Tim Scholta, Jun Xing, Vikas Bhuria, Bence Sipos, Ludwig Wilkens, Toan Nguyen Linh, Thirumalaisamy P Velavan, Przemyslaw Bozko, Ruben R Plentz   +10 more
openaire   +2 more sources

Frontline Siltuximab and Rituximab in TAFRO syndrome: A case report

European Journal of Haematology, 2020
No abstract available.
Monia Marchetti, Elda Feyles, PierLuigi Zinzani   +2 more
openaire   +3 more sources

Siltuximab: A Targeted Therapy for Idiopathic Multicentric Castleman Disease

Immunotherapy, 2015
Human herpes virus-8 (HHV-8)-negative or idiopathic multicentric Castleman disease (iMCD) is a rare and deadly disorder that sits at the nexus of hematology/oncology, virology and immunology. Management of iMCD has been challenging due to limited understanding of etiology and pathogenesis and few treatment options. The recent approvals in North America,
David C, Fajgenbaum, Razelle, Kurzrock
openaire   +2 more sources

Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma

Expert Opinion on Investigational Drugs, 2017
The role of interleukin-6 (IL-6) in tumorigenesis and in particular in haematological malignancies is crucial. On the basis of the favourable results obtained in the subset of multicentric Castleman disease (MCD), Siltuximab, a chimeric, human-murine, immunoglobulin (Ig) Gk monoclonal antibody directed against human IL-6 has been evaluated in ...
Ferrario, Andrea, Merli, Michele, Basilico, Claudia, Maffioli, Margherita, PASSAMONTI, FRANCESCO   +4 more
openaire   +3 more sources

Siltuximab in transplant-ineligible patients with myeloma

The Lancet Oncology, 2014
In patients who are transplant-ineligible with newly diagnosed multiple myeloma, the addition of siltuximab (an anti-interleukin-6 monoclonal anti body) to the bortezomibmelphalan-prednisone (VMP) regimen does not improve complete response, progression-free survival (PFS), and overall survival, but improves very good partial responses (VGPR), new ...
openaire   +1 more source

Siltuximab Reverses Muscle Wasting In Patients With Multicentric Castleman’s Disease

Blood, 2013
Abstract Introduction Multicentric Castleman’s disease (MCD) is a rare lymphoproliferative disease characterized by fevers, night sweats, fatigue, anorexia, and wasting. Interleukin-6 (IL-6) plays a pivotal role in MCD and is involved in muscle wasting.
Marcotte Kirk, Razelle Kurzrock, Frits van Rhee, Qi Ming, Jessica Vermeulen, Vickie E Baracos, Sunita Ghosh, Michael Sawyer   +7 more
openaire   +1 more source

Siltuximab, a Novel Anti–Interleukin-6 Monoclonal Antibody, for Castleman's Disease

Journal of Clinical Oncology, 2010
Purpose Interleukin-6 (IL-6) has emerged as a key factor in the pathogenesis of the atypical lymphoproliferative disorder Castleman's disease (CD). Siltuximab is a new anti–IL-6, chimeric monoclonal antibody with potential therapeutic benefit in patients with CD.
Frits, van Rhee, Luis, Fayad, Peter, Voorhees, Richard, Furman, Sagar, Lonial, Hossein, Borghaei, Lubomir, Sokol, Julie, Crawford, Mark, Cornfeld, Ming, Qi, Xiang, Qin, Jennifer, Herring, Corey, Casper, Razelle, Kurzrock   +13 more
openaire   +2 more sources

FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease

Clinical Cancer Research, 2015
Abstract On April 22, 2014, the FDA granted full approval to siltuximab (SYLVANT for injection; Janssen Biotech, Inc.), a chimeric human-mouse monoclonal antibody to IL6, for the treatment of patients with multicentric Castleman disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative ...
Albert, Deisseroth, Chia-Wen, Ko, Lei, Nie, Jeanne F, Zirkelbach, Liang, Zhao, Julie, Bullock, Nitin, Mehrotra, Pedro, Del Valle, Haleh, Saber, Christopher, Sheth, Brenda, Gehrke, Robert, Justice, Ann, Farrell, Richard, Pazdur   +13 more
openaire   +2 more sources